The stem cell inhibitor, macrophage inflammatory proteinl a (MIP-la) or LD78, protects multipotent hematopoietic progenitors in murine models from the cytotoxic effects of chemotherapy. Clinical use of human MIP-la during chemotherapy could therefore lead to faster hematologic recovery and may allow dose intensification. We have also shown that human MIP-la causes the rapid mobilization of hematopoietic cells, suggesting an additional clinical use in peripheral blood stem cell transplantation. However, the clinical evaluation of human MIP-la is complicated by its tendency to associate and form high molecular weight polymers. We have produced a variant of rhMIP-la, BB-10010, carrying a E ARE INTERESTED in exploring the clinical application of both the myeloprotective'-6 and progenitor mobilizing7 activities of recombinant human macrophage inflammatory protein-la (rhMIP-la). The clinical use of rhMIP-la is compromised because, at physiologic ionic strength, the 8-kD monomeric molecule self-associates to form heterogeneous, multimeric complexes of mass ranging from 100 to more than 250 D.' We and others have determined that, using certain solution conditions, such as high salt concentration, it is possible to dissociate MIP-la.3.X-II However, such conditions might not maintain the dissociated state in vivo and would unacceptably limit the conditions that could be used in manufacture. Biophysical characterization of the polymerization pathway showed that high ionic strength buffers substantially reduced multimerization beyond a tetramer. This indicated that electrostatic interactions were important in the formation and stabilization of higher molecular weight complexes. To dissociate rhMIP-1 a to its monomeric subunits, relatively harsh conditions of acidified acetonitrile were required, suggesting that the major stabilizing force for the tetrameric unit is hydrophobic.x To avoid these production and formulation problems of human MIP-la, we have used mutagenesis to improve the solution characteristics of the protein while retaining its biologic potency.'* A similar approach has been described by Graham et a1,I3 who used a mutagenesis strategy to prevent the aggregation of murine MIP-la. Based on evidence that the C-terminus of rhMIP-la was important in multimerization,' they made three variants with successive neutralization of acidic residues in the C-terminal a helix. Because the C-terminal charge was neutralized, the size of the variant decreased. We chose to adopt a more extensive mutagenesis strategy that did not assume which residues were involved in polymerization. This involved more than 150 variants of the 69 amino acid human protein." Our goal was to identify a variant with improved solution properties, wild-type activity, and minimal structural perturbation.
The stem cell inhibitor, macrophage inflammatory proteinl a (MIP-la) or LD78, protects multipotent hematopoietic progenitors in murine models from the cytotoxic effects of chemotherapy. Clinical use of human MIP-la during chemotherapy could therefore lead to faster hematologic recovery and may allow dose intensification. We have also shown that human MIP-la causes the rapid mobilization of hematopoietic cells, suggesting an additional clinical use in peripheral blood stem cell transplantation. However, the clinical evaluation of human MIP-la is complicated by its tendency to associate and form high molecular weight polymers. We have produced a variant of rhMIP-la, BB-10010, carrying a E ARE INTERESTED in exploring the clinical application of both the myeloprotective'-6 and progenitor mobilizing7 activities of recombinant human macrophage inflammatory protein-la (rhMIP-la). The clinical use of rhMIP-la is compromised because, at physiologic ionic strength, the 8-kD monomeric molecule self-associates to form heterogeneous, multimeric complexes of mass ranging from 100 to more than 250 D. ' We and others have determined that, using certain solution conditions, such as high salt concentration, it is possible to dissociate MIP-la.3.X-II However, such conditions might not maintain the dissociated state in vivo and would unacceptably limit the conditions that could be used in manufacture. Biophysical characterization of the polymerization pathway showed that high ionic strength buffers substantially reduced multimerization beyond a tetramer. This indicated that electrostatic interactions were important in the formation and stabilization of higher molecular weight complexes. To dissociate rhMIP-1 a to its monomeric subunits, relatively harsh conditions of acidified acetonitrile were required, suggesting that the major stabilizing force for the tetrameric unit is hydrophobic.x
To avoid these production and formulation problems of human MIP-la, we have used mutagenesis to improve the solution characteristics of the protein while retaining its biologic potency.'* A similar approach has been described by Graham et a1,I3 who used a mutagenesis strategy to prevent the aggregation of murine MIP-la. Based on evidence that single amino acid substitution of Asp26 > Ala, with a reduced tendency to form large polymers at physiologic pH and ionic strength. This greatly increases its solubility, facilitating its production and clinical formulation. We confirmed the potency of BB-l0010 as a human MIP-la-like agonist in receptor binding, calcium mobilization, inhibition of colony formation, and thymidine suicide assays. The myeloprotective activity of BB-l0010 was shown in a murine model of repeated chemotherapy using hydroxyurea. BB-l0010 is therefore an ideal variant with which to evaluate the therapeutic potential of recombinant human MIP-la.
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the C-terminus of rhMIP-la was important in multimerization,' they made three variants with successive neutralization of acidic residues in the C-terminal a helix. Because the C-terminal charge was neutralized, the size of the variant decreased. We chose to adopt a more extensive mutagenesis strategy that did not assume which residues were involved in polymerization. This involved more than 150 variants of the 69 amino acid human protein." Our goal was to identify a variant with improved solution properties, wild-type activity, and minimal structural perturbation.
We have identified a variant, BB-10010 (Fig l) , carrying a single amino acid substitution of Asp26 > Ala with significant changes in its solution characteristics. The solution properties of rhMIPla and BB-10010 were compared using size exclusion chromatography and analytical ultracentrifugation. The biologic activities of the two proteins were compared using receptor binding, calcium mobilization, inhibition of colony formation, and thymidine suicide assays. The myeloprotective activity of BB-10010 in vivo was shown in a murine model of repeated chemotherapy using hydroxyurea. We show here that BB-l0010 has improved solution characteristics but retains the biologic activity of rhMIP-la. We are now evaluating its clinical potential in studies of both stem cell protection and peripheral blood stem cell transplantation.
MATERIALS AND METHODS
Source of MIP-la. rhMIP-la and BB-10010 were expressed from synthetic wild-type and Asp26 > Ala variant genes, respectively, according to the methods of Clements et al. 4 Both genes encoded a 69 amino acid protein based on the sequence of LD78,I4 with an N-terminus of S-L-A-A-D- (Fig I) . Protein was prepared from cell-free supernatants according to the methods described in Patel et al.* The identity and purity of the rhMIP-la and BB-10010 were confirmed using electrospray mass spectroscopy, N-terminal sequencing, and analytical reverse-phase high performance liquid chromatography (HPLC). The protein contained less than 2 endotoxin unitdmg as determined by the limulus amebocyte lysate (LAL) assay.
Mice. 
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(IMDM) containing 20% (voUvol) horse serum, 2% (voUvol) X63AG8/653 conditioned medium,I6 and 2 mmoVL glutamine. The human monocytic cell line THP-l (ECACC NO. 88081201) was cultured in RPMI 1640 medium containing 2 mmoVL glutamine and 10% (vol/vol) fetal calf serum. The cells were maintained at a density of between I and 8 X IO5 cells/mL and incubated at 37°C in an atmosphere of 95% air/5% CO,. L-929 conditioned medium was prepared according to Heyworth and Spooncer." AFI-19T cell conditioned medium was prepared by growing the cells in IMDM containing 10% (vol/vol) fetal calf serum for 3 days at 37°C in an atmosphere of 95% air/5% CO,. The medium was discarded and the cells were refed with fresh medium. After a further 4 days, the conditioned medium was collected and stored at 4°C before use.
Size exclusion fastprotein liquid chromatography. Size analysis of the rhMIP-la and BB-10010 samples was performed by size exclusion fast protein liquid chromatography (SE-FPLC) using a Pharmacia Superdex G-75 HR 10/30 column (Pharmacia, Uppsala, Sweden). Samples at 1 mg/mL in Dulbecco's modified phosphatebuffered saline (PBS) without calcium, magnesium, or bicarbonate (PBS "A") were centrifuged at 10,000g for 3 minutes and 50 pL of the supernatant was loaded onto a column pre-equilibrated with PBS "A". The sample was then eluted at a flow rate of 1 mL/min and the absorbance of the eluate was monitored at 280 nm. The elution profiles of rhMIP-la and BB-10010 were compared with elution profiles obtained with gel filtration molecular weight markers (BioRad Laboratories, Hercules, CA).
Sedimentation equilibrium analytical uftracentnfugation (AUC). Sedimentation equilibrium AUC was performed using a Beckman XLA analytical ultracentrifuge (Beckman Instruments Inc, Palo Alto, CA) with absorbance optics. Protein samples at 0.1 mg/mL were loaded in a six sector cell with PBS "A" in the reference sector.
The samples were spun at 15,000 rpm at 25°C for 18 hours to reach equilibrium and scanned at 230 nm as a function of radius. The scan was repeated after a further 3 hours of centrifugation to confirm that equilibrium had been achieved. Data were analyzed using Microcal Origin software (Microcol Software, Inc. Northampton, MA) for the Beckman XLA analytical ultracentrifuge. They were fitted to a model assuming a single ideal species (Ideall) to provide an estimate of the weight average molecular weight. Data sets shown are an average of 20 scans in 0.001 cm increments across the radius of the rotor.
Receptor binding assay. rhMIP-la was radiolabeled under contract (Amersham International plc, Slough, UK) using the Chloramine T method to a specific activity of 250 pCi/pg. In receptor binding assays, 1 X IO6 murine FDCP-mix A4 or human THP-1 cells were dispensed into Eppendorf tubes containing different amounts of unlabeled rhMIP-la or BB-10010 and 3.85 ng/mL ['251]-rhMIP-1a in a total volume of 250 pL of binding medium (RPMI 1640, 20 mmoVL HEPES, and 1 mg/ml bovine serum albumin [BSA]). After incubation at 25°C for 60 minutes, 1 mL of PBS without calcium (PBS "A") was added and mixed, and the cells were harvested by centrifugation. The supernatants were removed and the cells were washed twice with 1 mL of PBS "A." Cell pellets were resuspended in 250 pL of PBS "A" and the radioactivity was determined in a gamma counter. The concentration of unlabeled rhMIP-la or BB-10010 required to reduce the binding of 3.85 ng/mL [1251]-rhMIPl a by 50% (IC5") on murine FDCP-mix A4 or human THP-l cells was estimated from a graph of counts bound against the concentration of cold ligand.
Calcium mobilization assay. Changes in the concentration of intracellular Caz' were followed using the fluorescent label FURA-2.18 THP-1 cells were harvested and resuspended to 2 to 3 X IO6 cells/mL in growth medium. FURA-2AM (Cambridge Bioscience, Cambridge, UK, 1 mg/mL in dimethyl sulfoxide [DMSO]) was added to 1 pmol/L and incubated for 45 minutes at 37°C in an atmosphere of 95% air/5% COz. The cells were washed and resuspended in Tyrodes buffer (10 mmoVL HEPES, 129 mmoVL NaCI, 8.9 mmol/L NaHC03, 2.8 mmoVL KCI, 0.8 mmoVL KH,PO,, 5.6 mmol/L dextrose, 0.8 mmol/L MgCIz, pH 7.4) to give 2 to 3 X IO6 THP-1 cells/mL. FURA-2 fluorescence emission intensity was measured at 37°C using a Perkin-Elmer LS-50 fluorimeter with a cell holder and built-in magnetic stirrer. The samples were excited at 340 nm with a IO-nm bandwidth and the emission was continuously recorded at 500 nm with a 5-nm bandwidth. FURA-2-loaded THP-1 cells (2 mL; 2 X lo6 cellslml) were transferred to a 4. 
, where F1 is the intensity before agonist addition, F2 is the peak intensity after agonist addition, FmaX is the intensity after digitonin addition, and F,,, is the intensity after EGTA chelation.
Isolation of FACS-I murine progenitors. Murine hematopoietic progenitor cells were isolated as a FACS-1 population from murine bone marrow by density gradient centrifugation and fluorescenceactivated cell sorting with wheat germ agglutinin (WGA) as described by Lord and Marsh." Briefly, low-density femoral marrow cells were obtained by density separation on metrizamide at 1.080 g/mL, labeled with fluorescein isothiocyanate (FITC)-conjugated WGA, and sorted on a Becton Dickenson FACSIV or FACSvantage flow cytometer (Becton Dickinson, Mountain View, CA). The windows were set to exclude small cells, large granular cells, and cells with low WGA-FITC. The cells were sorted at approximately 3,000 cells/s. On completion of the first sort (2 to 3 hours), the WGA-FITC-labeled low-density mononuclear cells were resorted at 300 cellsls using the same parameters.
Agar colony-forming unit assay. rhMIP-la or BB-10010 (15 pg to 500 pg/mL) was added to FACS-I cells (3, [volhol] AFI-19T conditioned medium, 2 mmol/L glutamine) at 3 X 10' cells/mL. The resuspended cells were dispensed as I-mL aliquots into 15-mL polypropylene tubes and incubated overnight at 37°C in an atmosphere of 95% air/ 5% CO,. The l-mL aliquots of cells were split into 0.5-mL duplicates. rhMIP-la and BB-IO010 at the required concentration was added to one of the duplicates and PBS (control) was added to the other duplicate and incubation continued. After 2 hours, 'H-thymidine (IO pL, I mCi/mL) was added to all appropriate tubes and incubation continued for 30 minutes. Thymidine incorporation was terminated by the addition of excess unlabeled thymidine (4 mL, 100 pglmL thymidine in IMDM). The cells were harvested and resuspended in 3 mL of plating medium and plated into 3 X 35 mm petri dishes as described above. The plates were incubated at 37°C in an atmosphere of 5% COz, 5% Oz in a humidified cabinet. After 7 to 12 days of incubation, the number of colonies was assessed microscopically.
Protection of hematopoietic progenitor cells from the cytutonic effects hydroxyurea in vivo by BB-10010. A murine model of repeated chemotherapy using hydroxyurea was used to show the in vivo myeloprotective activity of BB-10010. Nine groups of five mice were injected intraperitoneally (IP) at 0 and 7 hours with 1 g k g hydroxyurea and with BB-l0010 or vehicle control (PBS "A") at 3 and 6 hours (day 0). Three of the nine groups received BB-I0010 at 100 pgkg, three groups received BB40010 at 500 pgkg, and three groups received PBS control, all injected subcutaneously. An additional three groups received PBS injected IP at 0 and 7 hours. PBS "A" was injected subcutaneously (SC) at 3 and 6 hours to act as vehicle controls for both hydroxurea and BB-10010 administration. One group of mice receiving each treatment was killed on day + I, day +2, and day +3. A pooled femoral bone marrow suspension was prepared using a single femur from each mouse in each group on days + l , +2, and +3 for colony-forming unit-spleen (CFU-S) assay. On days + 1 and +2, unpooled bone marrow cell suspensions were prepared from mice in each group to allow an assessment of the CFU/femur in individual mice using methylcellulose CFU assays.
CFU-S assay. CFU-S were assayed in irradiated (15.25 GyWCo y-rays; dose rate, 0.95 Gylh) mice as previously described.' The irradiated recipient mice (lO/group) were injected intravenously with 0.2 mL of a femoral bone marrow suspension and killed 8 days later for spleen colony counting.
Methylcellulose CFU ussays. Femoral bone marrow suspensions were plated in methylcellulose semisolid medium (Readymix HCC3430; Stem Cell Technologies Inc, Vancouver, British Columbia, Canada) containing a complex mixture of growth stimulatory cytokines, supplemented with additional stem cell factor (SCF 20 ng/mL), and incubated at 37°C and 5% CO, and 5% 0,. The number of colonies was assessed microscopically after 7 days of growth. The colonies were counted regardless of size and cell type, but were generally CFU-granulocyte-macrophage (CFU-GM) colonies of greater than 40 cells. The number of colonies per nucleated white blood cell plated was calculated. The results were transformed into methylcellulose CFU per femur for each animal. Comparisons between treatments were made using the unpaired Student's r-test. and BB-l0010 were initially compared using SE-FPLC ( Fig  2) . The elution profiles are strikingly different. The rhMIPl a peak is asymmetric, with the bulk of the protein excluded from the column and the remainder trailing to positions equivalent to lower molecular masses. This reflects a heterogeneous mixture of soluble multimeric complexes ranging in mass from approximately 20 to greater than 100 k D . In contrast, BB-10010 elutes as a symmetrical peak, within the analytical range of the column. By comparison with molecular weight markers, the BB-IO010 peak was estimated to be between 17 and 44 k D . A more rigorous comparison of the molecular masses was obtained by sedimentation equilibrium AUC at 0.1 mglmL in PBS "A" (Fig 3) . The samples reached equilibrium after centrifugation at 15,OOO rpm for 18 hours. The absorbance at 230 nm was plotted against the position in the cell (radius) and a line of best fit was calculated. The calculation assumes that the protein does not self- associate or interact with the PBS "A" or the cell (a single component ideal solution) and forms a model with which to test these assumptions. The differences between the data and the best fit model, the residuals, are also plotted against cell radius. A good correlation between the data and the model is indicated when the residuals are randomly distributed across the radius. The weight average molecular weight of rhMIP-la was 100 kD. rhMIP-la is a poor fit to the model, as shown by the nonrandom residuals. The higher weight average molecular weight of rhMIP-la and the distribution of the residuals indicate an aggregating system. In comparison, the data for BB-10010 are a good fit to the model because the residuals are randomly distributed across the radius. Thus, BB-10010 behaves as if it does not self-associate. The average molecular weight of BB-10010 was 19 kD.
RESULTS

Comparison
Comparison of the receptor binding and signal transduction activities of rhMIP-la and BB-10010. The effect of the Asp26 > Ala substitution on the biologic activity of BB-10010 was assessed using receptor binding and signal transduction assays. The receptor binding activities of rhMIP-la and BB-10010 were compared on murine FCDPmix A4 cells (Fig 4) . This assay measured the concentration of unlabeled rhMIP-la or BB-10010 required to reduce the binding of 3.85 ng/mL ['2SI]-rhMIP-la on murine FDCPmix A4 cells by 50% (ICso). ICso values of 3.25 2 0.03 ngl mL for rhMIP-la (mean 2 SEM; n = 84) and 7.71 2 0.55 ng/mL (mean 2 SEM; n = 10) for BB-10010 were estimated.
The increase in IC5' value for BB-10010 was statistically significant (P < .OOOl, using the Student's t-test).
The abilities of rhMIP-la and BB-10010 to transduce a signal at MIP-la receptors on THP-l cells were compared by estimating the increase in intracellular free calcium ions as a function of agonist concentration (Fig 5) . The responses induced by rhMIP-la and BB-10010 were similar in the linear portion of the assay and were between 10 and 40 ngl mL of either protein. BB-10010 may induce a greater response than rhMIP-la at the extremes of the dose response presented, but the sensitivity of the assay is compromised at these agonist concentrations.
Agar CFU assay. The inhibitory properties of rhMIP-la and BB-10010 on stem cell growth were compared using their ability to inhibit the formation of FACS-l colonies in the agar CFU assay as a surrogate parameter?' Significant inhibition of colony formation was obtained with doses of 15 nglrnL or greater of both proteins (P < .05), at which an approximately 25% reduction in colony number was observed (Fig 6) .
Thymidine suicide assay. To obtain an in vitro assessment of the myeloprotective activity of BB-10010, we used the 3H-thymidine suicide assay to compare the abilities of rhMIP-la and BB-10010 to reduce the percentage of FACS-1 progenitors in cycle (Fig 7) . Half-maximal protection was observed between 15 pg/mL and 1.5 nglmL for both proteins; thus, both had similar potencies as assessed by their ability to inhibit the cycling of purified murine progenitors. 
Protection of multipotent hematopoietic progenitor cells from the cytotoxic effects of hydroxyurea in vivo.
We used a murine model of repeated chemotherapy with hydroxyurea to show the in vivo myeloprotective activity of BB-l0010 on multipotent (CFU-S) hematopoietic progenitors (Fig 8) . This assay has previously been used to show a protective effect with rmM1P-1m6 BB-10010 treatment gave increased CFU-S survival seen on day + l . On day +2, the BB-l0010 protected groups recovered to control levels, whereas the unprotected group was still depleted of C m -S . By day +3, the unprotected group recovered to control levels and the BB-10010 protected groups displayed a slight overshoot. This experiment showed that BB-l0010 retains the multipotent hematopoietic progenitor protection activity associated with rMIP-la.
Protection of lineage-restricted hematopoietic progenitor cells from the cytotoxic effects of hydroxyurea in vivo. In addition to the myeloprotective effects of BB-l0010 on multipotent hematopoietic progenitors (CFU-S), we also assessed the effect of BB-10010 on the survival and repopulation of more mature, lineage-restricted progenitors, using the methylcellulose CFU assay (Fig 9) . On day + I , hydroxyurea caused a significant reduction in the mean CFU per femur compared with control. Protection by BB-100 I0 on day + 1 posttreatment was not significant. However, by day +2, significant differences between treatment groups were apparent. In contrast to the group receiving hydroxyurea alone, the groups receiving 100 pg/kg and 500 pgkg doses of BB-10010 had CFU per femur counts that were statistically indistinguishable from the control group. This shows that BB-10010 treatment leads to an increased rate of recovery in more committed progenitors.
DISCUSSION
Since the discovery of the stem cell inhibitor,' later identified as mMIP-la,Z') the use of such a regulator of stem cell division as a protective agent has been an attractive possibil- ity. The identification of its human h o m~l o g u e~~~' and the ability to prepare large quantities of pure protein for preclinical studies4 brought the clinical evaluation of stem cell inhibitors a step closer. Importantly, these advances allowed a clear demonstration that stem cell inhibition could lead to protection in vivo. Thus, rmMIP-la has been shown to protect multipotent hematopoietic progenitor cells (CFU-S) from the cytotoxic effects of hydroxyurea in vivo in a murine model of repeated cycles of chemotherapy.6 Using rhMIPl a , stem cell protection was shown to reduce the duration of neutropenia associated with cytosine arabinoside administration in a murine model.5 More recently, the observation that rMIP-la can mobilize hematopoietic stem cells means that it might have a role in peripheral blood stem cell mobili~a t i o n .~ These preclinical observations were sufficiently compelling for us to test the clinical potential of MIP-la. However, the clinical development of MIP-la was complicated by its tendency for self-association. This property led to difficulties in controlling production processes, in pharmaceutical formulation, and in the stability of the final product.
We have used mutagenesis to improve the solution properties of rhMIP-la and hence facilitate its clinical development. During our mutagenesis program,'* which will be reported in detail elsewhere, we found that a number of amino acid substitutions that altered solution properties also de-I -1 creased biologic potency. We therefore undertook to assess the activity and detailed solution characteristics of a larger number of variants to identify a suitable candidate for clinical development. In our library of rhMIP-la mutants, we identified several single amino acid substitutions that yielded proteins that are substantially dissociated in PBS. These include variants that are predominantly monomeric, dimeric, or tetrameric when analyzed using AUC. These results show that it is possible to manipulate the self-association pathway of rhMIP-la by mutagenesis. We have also identified regions other than the C-terminus of MIP-la that can be manipulated to give active nonaggregating variants. BB-10010 was chosen for clinical evaluation because of its molecular weight, its activity, and the fact that it has a single amino acid substitution, thus reducing the potential for immunogenicity.
Comparison of the SE-FPLC and AUC data for both rhMIP-la and BB-l0010 show that the Asp26 > Ala substitution in BB-10010 greatly affected the solution properties, producing a more homogeneous solution with an average molecular weight of 19 kD in PBS "A" at 0.1 mg/mL. It is impossible to determine the precise association state of BB-10010 from these data, although it falls in the range dimedtrimedtetramer in these conditions. In comparison, the rhMIP-la is clearly heterogeneous, with an average size of at least 100 kD. This difference is striking at higher protein concentrations and is emphasized in the formulations shown ( Fig IO) . As a result of the polymerization observed on the molecular scale by the SE-FPLC and AUC, the rhMIP-la solution contains a large amount of aggregated material, with molecular species so large that they become insoluble. Under these conditions, BB-10010 is still soluble.
The biologic activity of MIP-la is initiated by the binding of the chemokine to receptors and subsequent signal trans-10010 had similar receptor binding and signal transduction activities to rhMIP-la. BB-10010 retained receptor binding activity, but with an ICso approximately twice that of rhMIPla on FDCP-mix A4 cells. We confirmed that BB-IO010 receptor binding was able to trigger signal transduction using a calcium mobilization assay. The human monocytic cell line THP-I was used in this assay because the FDCP-mix A4 cells were not suitable. Both cell lines possess MIP-la receptors with similar affinities for rhMIP-la and BB-10010 duction.~x.?'.?3 It was therefore important to show that BB-
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(data not shown). The rhMIP-la and BB-10010 dose responses were similar over the linear portion of the calcium mobilization assay. This suggested that the twofold increase observed in the receptor binding ICso of BB-10010 was pharmacologically insignificant. In addition to retaining receptor binding and signal transduction activities, BB-10010 retains the stem cell inhibitory properties of rhMIP-la. Thus, the in vitro growth-inhibitory activities of rhMIP-la and BB-10010 in the agar CFU assay, and their ability to protect progenitors from thymidine suicide was similar.
BB-IO010 retains the ability to protect murine multipotent (CFU-S) and lineage-restricted hematopoietic progenitor cells from the cytotoxic effects of hydroxyurea in vivo. Approximately twice as many multipotent hematopoietic progenitor cells, capable of forming spleen colonies, survived hydroxyurea in groups that were protected by BB-10010. Furthermore, they recovered to control levels 1 day faster.
BB-10010 also effected a more rapid recovery of lineagerestricted hematopoietic progenitors. These results confirmed the in vivo activity of BB-10010 and showed its suitability for clinical evaluation.
Some nonaggregating preparations and variants of rhMIPla, like BB-10010, retain biologic activities and have led to the suggestion that the monomer is the active form of the molecule at the It has been reported that monomeric interle~kin-8,~~.*~ MCP-I, and 1-309 are active as monomers at physiologically relevant concentrations? It is tempting to assume that the MIP-la monomer is the active form because it suggests a commonality of action throughout the chemokines. Our structure-activity data do not address this issue and cannot be used to conclude that the monomer is the active species. The aggregation problems of rMIP-la caused Paolini et a124 difficulties in AUC analysis of their preparations. Because of the improved solution properties of BB-10010, we have not experienced these problems.
BB-10010 is a genetically engineered variant of rhMIPla, with a single amino acid substitution of Asp26 > Ala that dramatically improves its pharmaceutical properties. It is active in a range of in vitro assays of biologic function and retains the ability to protect hematopoietic progenitor cells from the myelosuppressive effects of hydroxyurea in vivo. The development of this agent now enables us to test the hypothesis that stem cell protection will enhance hematopoietic recoveries in cancer patients undergoing intensive chemotherapy. BB-10010 is currently in clinical trials to evaluate its potential as an adjunct to chemotherapy regimens and as a mobilizer of hematopoietic stem and progenitor cells. For personal use only. on May 29, 2017. by guest www.bloodjournal.org From
